and generation you have what they've been able to do, but unfortunately with them there's nobody coming behind to really start competing against them. and there seems to be a bit of complacency, a bit of what this team. oh okay, fine. we've done. well, we came in 3rd place, we competing, we're good enough, but you need a little bit more of that. you need to do a lot better, especially like it's a team that's a competitive animal in creation. that's where end of leading amount. absolutely. now day 13 of cut a 2022 sees the group stage, reach its conclusion with the deciding matches in groups g and h. the action gets underway at 1500, gmc with gonna against euro. glad alt jennifer stadium. but south korea playing the already qualified portugal at the same time at education city, brazil, also through a head of the 1900 gmc kick off with cameroon, which is taking place at lou sale. and that is being played at the same time as serbia and switzerland that matches taking place at stadium 9 at 7 full. so plenty

to look forward to on the last day of the group stages at with tournament, our team will have it all covered right here on al jazeera dr. creature at the top stories here on al jazeera in woke up football news for time champions, germany as he just had a out of the world cup at the beach stage. the 2nd tournament one that be plus the week a 40, but it wasn't enough for them and both teams went out well that result in short, germany went out, meant joy for japan. that to one when the same means that he explained through despite that defeat joyful morocco as well there into the law. 16 with 2 goals in the 1st half a bit, canada to want to finish top, beth 1st on the rocker. i have reached the round of 16 since 1986 french liter. manion macro is in the u. s. m. his 1st visit of the country since president biden took office. the leaders of discuss a number of global issues and i'm jointly condemned. russia's warn ukraine. you can,

unions urging china to use its influence on russia to end the war in ukraine, but china's presidents as a political solution as needed. she, she being held talks in beijing with european council of president charles michelle . but tony does met at a time of strained relations. it's partly due to china's treatment of the week. a minority. michelle said he raised the issue of human rights. human rights are just and i welcome the ready to resume you china human rights dialogue. we will follow up on distributions because this format this not transients for more than 3 years. so this is an important signal dialect low as to focus. why does human rights policy issues and an individual chooses? the spokesman for south africa as president says 0, my puerto is engaging with members of the ruling african national congress over his political future. it comes as an independent panel of found. he violated his own

office from a poser was investigated after millions of dollars hidden inside a sofa, allegedly stolen from his farm. the army and the democratic republic of congo says m. $23.00 rebels and their allies have killed 50 civilians in the eastern time of kinship. the group denies responsibility. people have been protesting against the violence. the kenning threatened a ceasefire in north kiva province negotiated at the weekend. so those are the headlines. the news continues here now to sierra after inside story stage, and thanks for watching bye for now. ah. a new drug is being touted as a breakthrough to find a cure for alzheimer's. it's the 1st treatment to slow the onset of the

degenerative disease, but it's not without risk. so how important is this trial and what will its impact be on millions. this is insightful. ah hello and welcome to the program. i'm hammered. jim john, japanese and american pharmaceutical companies have published the results of a trial which is being held as a breakthrough in the fight against alzheimer's disease. the data showed how a new drug can significantly slow down cognitive decline in some patients by 27 percent. the 18 month trial involved nearly 2000 participants who were in the early stages of the illness. health experts say one person develops dementia every 3 seconds. alzheimer's is the most common cause of dementia. the number of people

suffering from the disease is expected to double every 20 years. worldwide. dementia costs are more than a trillion dollars globally, about a 3rd of the u. k. annual g d. p. those figures include direct medical care and social and unpaid costs. and early detection of neuro degenerative disorders is crucial for recognizing signs of alzheimer's or cognitive decline will bring in our guests in a moment. but 1st, this report from harry faucet in london for over 30 years. scientists have tried and failed to design a drug that tackles the cause, not the symptoms of alzheimer's disease. now comes the 1st evidence of real success and antibody infusion that attacks a specific protein in the brain. slowing the development of early stage alzheimer's by around a quarter professor john hardy, 1st developed the theory of it. we said that this approach might work 30 years ago . and you know, if you'd asked me 30 years ago how it would take, i'd say 5 to 10 years. so for me it's,

it seems definitely momentous. i think for patients, it's a real step forward, a real step forward. and it's going to take a couple of years to get it into the system. it's patients like john teeling in the early stages of the disease who stand to benefit the most. john says he felt the ground open up when he was diagnosed. he'd embrace anything that gives him more time with his wife and family. you put him on, you know what you're going to end up like. and you know, there's nothing you can do about it. but you can't worry about it because there's no way you can do someone be accepting of it. the new drug laquanda mab inhibits the build up in the brain of a protein called be to amyloid visible is so called plaques in the brains of alzheimer's patients. nearly $1800.00 patients around the world took part in the study which showed a 27 percent slow down in the deterioration of their cognitive skills over 18

months. but it's approved. the treatment will be laborious and costly to administer through blood infusions twice a month. and will also require major investment in screening for the disease to catch it sufficiently early. and at the moment we do that through pet scans, altering cerebral final fluid testing from a lender puncture. and that is we need to broaden access to ways in which we can have access to those kind of test. we also want to see new techniques that are quicker and faster and potentially cheaper. for example, blood, her 30000000 people around the world suffer with alzheimer's. in itself, just one form of dementia, much difficult and costly work remains before treatments, let alone cues a widely available. but this is a hugely significant 1st step. harris will sit al jazeera london. ah. all right, let's go ahead and bring in our guests in glasgow dream sutherland, who uses social media to raise awareness about all timers after his mother was

diagnosed. he's also a social media ambassador for all time or scotland and live in belgium. dr. bart district director of the u. k. dementia research institute. and in cambridge, susan cole, hoss director of research at alzheimer's research. u. k. a warm welcome to you all, and thanks so much for joining us on in. so sorry today as soon cause, let me start with you today. the results that have been released as far from this clinical trial of kind of how big a breakthrough is this? this is a historic moment for all 3 years because it's the 1st time that we've actually shown that a drop that you give to people can low cost to decline. and really what we've been waiting for the field for many, many years. and it's a combination of many years of research, patient effort, and people participating in clinical trials as fantastic news for the field. it shows that dimension is simply an image age and we're really need to lie to our

research u. k. and just call has let me also just follow up with you. i mean, you mentioned that this is showing that it was, that is slowing cognitive decline. this clinical trial found that after 18 months, patients receiving kind of mob declined slower than those taking a placebo. that difference is that enough to be considered a clinic clinically meaningful treatment. we don't really have consensus on that the moment, but there are a couple of big unknown. i think 1st is this, this drug is gives a modest effect. i think it's really important to manage people expectations on that, but this is a 1st generation drug and we wouldn't, wouldn't normally see major impact for 1st generation drug. i think the 2nd thing to remember is that for somebody who is developing all timers, disease in the early stages of all our disease was meaningful. could be really different. so they could give people more time when their families live

independently. and i think that is not to be understated for a patient community that has waited for decades for treatment. and i think finally, we don't have yet because it's too early, long term days on whether intervention or early or can actually change the trajectory of the disease later on. those studies that the long term studies are reflect that they long term will be really key in determining whether or not we see a fax, much longer than the 18 months that we, we study, se grooms havilland. i saw you nodding along to some of what susan cole house was saying there, and i want to ask you as someone who has very publicly documented the tool that alzheimers has taken on your mother and on your family. what was your initial reaction when you heard the news about the results of this trial? the story because those gets some hope for the future, for people whose family and loved ones are diagnosed with the disease. because when

my mom was diagnosed, that wasn't edison, i hope so. defeats kind of sealed about point where it says at least and that a direction and graham, how long ago was your mother diagnose. and what kind of a told that take of finding that out for you and for her and for other members of your family. so she was diagnosed over 70 years ago now. and it's been quite slow, but more sped up more recently. and i think the tool has been very, as a, has go to, but mainly i meant to impact because you're, you're watching your loved one. i'm watching my mom a slowly fade away in front of me as i hated all the family and friends watching that happen. because there's nothing you can do. ready you feel very was and you know, you need to take care of guessing because there's not a lot of funding in place to help caters and a lot. ready lake,

my cell from assess the house in waste to do with thought bart, to super this approach to treating alzheimer's. this has been in the works as i understand it for over 30 years. why did it take this long and, and what's the difference between this form of treatment and other forms of treatment that have been attempted in the past? and that's a big question. you know, so 1st of all, why does it take so long? i think the brain is one of the most difficult, but i think that we all agree that it's a very difficult organ, much more difficult than anything else we study. there's also, it's also very protected from an environment. so that means it's getting medication in the brain. it's very difficult. but if you really ask me why it has taken so long, i think it's because the street has hugely being underfunded, overall is yours. and. and i think that that if you, if you compare each for instance, if you'd like cancer where we have seen a lot of progress, i think it's

a 15 folds difference. so it just takes much more time to get your money together to do your investigations that do best things. so that's for me to, to reasons. it's a great difficult problem. and it's an understanding things. and then 2 ways. org saying and how it compares we dollars. so the genetic proof that i'm a large is i can, relation in the brain are closely related to the disease has been there for many years. but because i was try, i was trying to tackle each failing. there was a lot of criticism and people started to think that it was not the right way. so it's for scientists like me, are very satisfied buying to see that we were always years on the right track in that a b have it's a necessity and you want to achieve something so adamant. are there other ways to prevent possible? i think that we need to find other ways to bust those. i mean are blacks because

the truck that you have now is far too expensive. if you want to roll out that all over the, for the, for the big 5000000 people with dementia, i went down to steve to meet him in 30 years. we need to have it as cheap. so that's the challenge now for the people in this area. and so we can talking about other examples, but i'll say it is also characterized by other allegiance, for instance. and the names on those are important, but they only diagnose and there's also a kind of inflammation in the brain and you start to understand those of those pathologies better and better. and so usually if you could have now also similar busters as, as the amino drink, we have now, that would be extremely helpful. and so, and so thus i am at, but that is the nice thing. now we have a breakthrough. and so it will be much easier now to best the wide he said to, to,

to go or go this through that you can do something about this disease and part to super. i just wanted drill down on, on something. you mentioned that because you were, you were mentioning this word amyloid in this new drug like panama, it's an antibody and, and it inhibits that build up in the brain of this protein called beta emily. now i don't know how it works, to be honest. okay, what was wondering if we can just briefly explain the lives if we just explain to our viewers what exactly is beta amyloid and what role does that play? yeah, well um to make it short so and our body produces all kinds of proteins which are basically the, the legal machinery to everything which you do all the days thinking, working, etc. and so the 1st small building blocks and so that i'm a lot of petrified is a small fragment or such ability book building global goals. they logically, i'm united precursor and so and a small fragment of that, i'm glad because it is, i'm a bad time. you can see there's

a small piece that breaks up over storm over over of soak, and that small piece accumulates in the brain and causes problems there. and that is wico van black. so i'm a lot of that ice is small pieces, accumulating a lot of glass in the blade. and the last, the things in the brain dream, i saw you nodding along a bit when bart was talking about the fact that from his perspective, one of the reasons is it's taken this long to get where we are right now is because the research into alzheimer's has been underfunded. do you think that the results of this clinical trial will spur more funding will? will this fight be better funded going forward? well hopefully because as, as she said i'll, i don't misses leek cancer is very mainstream. and i'll say moses very, very underfunded and not really spoke about as much as all lyla back alice's out there. and cancer has a lot of choose to. i'm treatment that is alzheimer's has,

has had muffin antonio. so hopefully this is a start of something that i can be spoke about more and more awarenesses raised to be able. ready to raise more money and funds for future and is this isn't co hossa of course it early detection of a neuro degenerative disorders. it's crucial for recognizing signs of, of alzheimer's or, or recognizing signs of cognitive decline overall. do you think we're going to see more breakthroughs on this front? i think we have to it is. we're now on the present system having our 1st generation of treatment that can flow disease processes. but there is no good unless we can start to identify and treat people early. we've seen a number of breakthroughs in the field that have been a little bit less high profile than this one over the years, starting to look at different, different and cheaper ways of identifying people who have the pathology in the

brain associated with all howard's disease. so measuring the ability to measure in the blood, for example, build up of amyloid and how and i think what we really need to do in the field is focus on how we get people diagnosed early into the clinic. offer access to drums when they finally do come through the regulatory crisis. also get them involved in research thing is that once in a lifetime, opportunity to take this breakthrough and actually turn it into more discoveries. what happens when we look lower, analyze in the brain? what are the other processes that are growing on how we start to target those? it's important to remember that there are over a 140 different treatments in clinical trials right now for all disease. most of those are not for amyloid. and i think it's probably this era of starting

to think about what would combination treatment look like. and how would we data a feels that will read a shift to dial over able to de bar to super. i saw you nodding along to some of what susan was saying there, it looks like you wanted to jump in, so please go ahead. oh no, i just agreed. reach between the 2 previous speakers, i think getting away from that, which is crucial if you want a society said that dimension we are holding are going to talk a lot about it today. but, but this is really essential that the lower governments are responsible people started to think how we are going to organize us because he's just, he's not going to me that he's all of a sudden know people he dementia anymore. so there will be big. ready small benevita girls and we will have to work hard to get new trucks. i usually get companies to meet with age because people remember that this was a disease for me,

not cure center and beginning we didn't really know how to do it. and then there was a drug which bore, but not fantastic. and then we got better and better drugs and nowadays week, we haven't queued for that for the, for that these are the. so i think that's, that is about that binds brain. we will see now for, for alzheimer's and we'll see that who improvements. and so we need to think both about about investing research investing, you cures, and also investing in with care and a good diagnosis of the patients who need to, to start today that in a professional way. and then a lot of point i also want to make because it is a lot of confusion about dementia outside of motor and so on. so didn't know majority disorders. and so you have all sound which levels of butter console disease you have also. i mean, i mean in terms of glucose bureaus demo, the same principle of all or disease. so i expect that to see very soon also

breakthroughs in these other areas based on the success maker. and it's very important also to realize that many people reach out diagnosed with alzheimer's, have mixed forms of literally duration. so it's not all the one process which is going on, but 2 or 3. and so the important to get broad in our portfolio and to do further the basic research, because that's usually not mentioned at all, but it's a big research which has made these possible. and he's a big research which will make it possible to pin solar. they got this little degeneration, so that's really that important as a message agreement. we ran a report earlier in the show from my colleague harry faucet and, and he said in his report that if this treatment is approved, it's going to be expensive. it's going to be difficult to administer. patients are going to need blood transfusions as i understand it twice a month. first of all, from your perspective, how difficult might it be for patients to actually get this treatment when and if it's approved and, and are you concerned that this treatment is going to be too expensive to become

widely available? yes, so it could cause issues. i mean, from my mom's perspective was it would be too, he thought of anything that came out any tapes and i am but even get them to clinics or anywhere to administer. that treatment would be very difficult. and the cost of that is already very difficult. as for my care of them to be able to afford things like that because a lot of kiddos are given up their jobs. and they all of you know, with their parents to look after them. so i don't know where the going to get the money from to do that, or as a government piece call, i would be very expensive. so i don't know whether to get funding fill out, which is why more awareness needs or ease reason for it to. ready to me is those funds for people grant? may i ask it because you have been so public and so open about what it's been like for you and your family to deal with alzheimer's. or if you had been told earlier

on in the course of this disease, that your mother suffering from that that this might have been a viable option. how, how would you have felt to think that you might have been able to get that extra time? i mean, what, what does the potential of this mean for those who are just now hearing about a diagnosis about potentially getting a little bit of extra time with a relative if, if this drug is ultimately approved. yes, that main point is team as team has been taken away from us as a family and moments whenever expedients. so even if it saves some payments as time that we need. and if we had the option then definitely look into it and do what we could to get it, i think. but it also was so you defax the the say the face could be. ready ready made by the, the positives off of their stock. if it does save time, if it goes what farm we spend more time to go or keep more. nobody's, and just have life events to get all that may not be with the experience. and we

don't know how long each stage last and i'll say must so like my mom can't speak very much anymore. so would be laces. even that team to come back and you'd be able to speak to me and know who was it. the pathos, susan, cause you heard graham there, talk about the fact that there are side effects and experts have already warned about potential side effects from, from this drug. what are some of the side effects? what are some other concerns going forward? i think the main side effect that many people are concerned about is something called our which is welling and or micro leads on the brain. and i think it's really important to note that this drug hasn't been through regulatory approval yet. i think the next step before it becomes more widely available that it needs to go and get regulatory approval. i think regulate in different countries

will look at those side effects in detail and way the effectiveness of the drug goals or the safety profile of the drug, and provide some recommendations about or, or even conditions about how it could be used and what monitoring people would need to go through in order to access the drug, but then just to, just to make a couple of like, one of one of the things for people to remember is not blood transfusions that people latest infusion, sorry, going to hospital for an hour or 2. i haven't drugged, put on a trip and have to drug and put into your system that way. right. and don't worry and find a very easy when things are right. and i think the other thing that people should be aware of each country will have it for deciding how the drug should be given and how much you know, whether, whether it's off the diets or pay for by that countries help. and so those conversations between the company and each of the different countries haven't

started yet, and we don't have any information on exactly what the drug would cost or how it would be administered. but i think it's fair to say that in most countries, certainly in the u. k. d, and i says, it's not ready to deliver this drug. and the time is now to get government charity clinicians and people affected by all timers, disease together to work out how we make the system ready to deliver treatment at large, not just specific treatment. we don't want to lose any time to do that because the research effort had been put in. and we want to make sure people can benefit as quickly as possible. graham, if there's one message you'd, you'd like to give to viewers out there about what, what, what kind of a toll this disease takes on families on individuals. what would that be? and it's completely changed, and it stills so much from you. and,

and i just think a lot of people think that passion, who's very old gets, as opposed to my mom was early onset and becoming younger. so it's something that's become an advocate problem. and the younger, younger on people need to speak more about and be more spoken about and let myself try to reach as much as possible because as life changing, it does affect everything. my life is made me grow very quickly because my mom is more with it at my age. it just has a. ready mentor for school tool on you and. ready families can change it. all right, well, we have run out of time, so we're going to have to leave our conversation there. thanks so much. all of our guests. graham sutherland bart, the stripper and susan cole house. and thank you to for watching. you can see the program again any time by visiting our website, algebra dot com. and for further discussion, go to our facebook page. that's facebook dot com,

forward slash ag inside story. you can also do the conversation on twitter or handle it at a time story for me, how much i'm drilling, holding here until 5 in the ah december as era, the middle east 1st woke up takes place and cuts off with 32 countries. buckling gets out for sports biggest prize immersive has no short documentary is african direct returns, showcasing african stories from african filmmaking. amid

a deep political crisis and worsening economic conditions, she nicea goes to the polls just months after a contentious constitutional referendum combating the climate in nature. crises of rise meet the people who believe global stems must change. joe biden host. some 50 lead us from across the african continent with the aim of underscoring the importance of us africa relations. december on al jazeera, join the debate. when we talk about climate change in africa, we should focus on education not mitigation on our online at your voice. it shouldn't be explained as what love what not is being right now is being everything that is going to benefit them on revealing new perspectives. like getting this out of proportion. no, no. his reach and has power is what is this proportionate? the stream we're a global audience becomes a global community on al jazeera. it's

already been voted the best airport in the world for 2022. now, how much international airport is about to faith, biggest tech? over $1200000.00 people are expected to visit with you in the world. cup majority of them will arrive here. it seems like the world cup has already started in this class in a fight they will travelling will cut for the wild card. this is the last barbecue before their trip with one thing in common. their support for the team, they know, the organizing committee says in terms of bookings on the official cut, our 2022 portal on p days. there are about 100000 and booking. that number is expected to increase as much as 30 percent by the time the tournament begin.